Literature DB >> 22948672

Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing.

Margaret J Lange1, Tarun K Sharma, Angela S Whatley, Linda A Landon, Michael A Tempesta, Marc C Johnson, Donald H Burke.   

Abstract

RNA aptamers that bind human immunodeficiency virus 1 (HIV-1) reverse transcriptase (RT) also inhibit viral replication, making them attractive as therapeutic candidates and potential tools for dissecting viral pathogenesis. However, it is not well understood how aptamer-expression context and cellular RNA pathways govern aptamer accumulation and net antiviral bioactivity. Using a previously-described expression cassette in which aptamers were flanked by two "minimal core" hammerhead ribozymes, we observed only weak suppression of pseudotyped HIV. To evaluate the importance of the minimal ribozymes, we replaced them with extended, tertiary-stabilized hammerhead ribozymes with enhanced self-cleavage activity, in addition to noncleaving ribozymes with active site mutations. Both the active and inactive versions of the extended hammerhead ribozymes increased inhibition of pseudotyped virus, indicating that processing is not necessary for bioactivity. Clonal stable cell lines expressing aptamers from these modified constructs strongly suppressed infectious virus, and were more effective than minimal ribozymes at high viral multiplicity of infection (MOI). Tertiary stabilization greatly increased aptamer accumulation in viral and subcellular compartments, again regardless of self-cleavage capability. We therefore propose that the increased accumulation is responsible for increased suppression, that the bioactive form of the aptamer is one of the uncleaved or partially cleaved transcripts, and that tertiary stabilization increases transcript stability by reducing exonuclease degradation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948672      PMCID: PMC3519987          DOI: 10.1038/mt.2012.158

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

1.  Localized expression of small RNA inhibitors in human cells.

Authors:  Cynthia P Paul; Paul D Good; Shirley X L Li; Annette Kleihauer; John J Rossi; David R Engelke
Journal:  Mol Ther       Date:  2003-02       Impact factor: 11.454

Review 2.  Advances in aptamers.

Authors:  Muhammad Ali Syed; Saima Pervaiz
Journal:  Oligonucleotides       Date:  2010-08-02

3.  An in vitro model of hepatitis C virion production.

Authors:  Theo Heller; Satoru Saito; Jonathan Auerbach; Tarice Williams; Tzivia Rachel Moreen; Allison Jazwinski; Brian Cruz; Neha Jeurkar; Ronda Sapp; Guangxiang Luo; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-08       Impact factor: 11.205

4.  An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.

Authors:  Charles Preston Neff; Jiehua Zhou; Leila Remling; Jes Kuruvilla; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; John J Rossi; Ramesh Akkina
Journal:  Sci Transl Med       Date:  2011-01-19       Impact factor: 17.956

5.  Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1.

Authors:  Laurent Chaloin; Maik Jörg Lehmann; Georg Sczakiel; Tobias Restle
Journal:  Nucleic Acids Res       Date:  2002-09-15       Impact factor: 16.971

6.  Triple ribozyme-mediated down-regulation of the retinoblastoma gene.

Authors:  C M Benedict; W Pan; S E Loy; G A Clawson
Journal:  Carcinogenesis       Date:  1998-07       Impact factor: 4.944

7.  Potent inhibition of human influenza H5N1 virus by oligonucleotides derived by SELEX.

Authors:  Congsheng Cheng; Jie Dong; Lihong Yao; Aijun Chen; Runqing Jia; Lifang Huan; Jianqiang Guo; Yuelong Shu; Zhiqing Zhang
Journal:  Biochem Biophys Res Commun       Date:  2007-12-17       Impact factor: 3.575

8.  Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84.

Authors:  Nina Kaiser; Peter Lischka; Nadine Wagenknecht; Thomas Stamminger
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

9.  Low-magnesium, trans-cleavage activity by type III, tertiary stabilized hammerhead ribozymes with stem 1 discontinuities.

Authors:  Donald H Burke; S Travis Greathouse
Journal:  BMC Biochem       Date:  2005-08-12       Impact factor: 4.059

10.  Instability of retroviral vectors with HIV-1-specific RT aptamers due to cryptic splice sites in the U6 promoter.

Authors:  Stephen E Braun; Xuanling Shi; Gang Qiu; Fay Eng Wong; Pheroze J Joshi; Vinayaka R Prasad; R Paul Johnson
Journal:  AIDS Res Ther       Date:  2007-10-17       Impact factor: 2.250

View more
  20 in total

1.  Activation of Innate Immune Responses by a CpG Oligonucleotide Sequence Composed Entirely of Threose Nucleic Acid.

Authors:  Margaret J Lange; Donald H Burke; John C Chaput
Journal:  Nucleic Acid Ther       Date:  2018-12-11       Impact factor: 5.486

Review 2.  Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.

Authors:  Martin Panigaj; M Brittany Johnson; Weina Ke; Jessica McMillan; Ekaterina A Goncharova; Morgan Chandler; Kirill A Afonin
Journal:  ACS Nano       Date:  2019-11-05       Impact factor: 15.881

Review 3.  Aptamers: novel molecules as diagnostic markers in bacterial and viral infections?

Authors:  Flávia M Zimbres; Attila Tárnok; Henning Ulrich; Carsten Wrenger
Journal:  Biomed Res Int       Date:  2013-09-05       Impact factor: 3.411

4.  RNA-protein interactions govern antiviral specificity and encapsidation of broad spectrum anti-HIV reverse transcriptase aptamers.

Authors:  Margaret J Lange; Phuong D M Nguyen; Mackenzie K Callaway; Marc C Johnson; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

5.  High-throughput sequence analysis reveals structural diversity and improved potency among RNA inhibitors of HIV reverse transcriptase.

Authors:  Mark A Ditzler; Margaret J Lange; Debojit Bose; Christopher A Bottoms; Katherine F Virkler; Andrew W Sawyer; Angela S Whatley; William Spollen; Scott A Givan; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2012-12-14       Impact factor: 16.971

6.  Potent Inhibition of HIV-1 Reverse Transcriptase and Replication by Nonpseudoknot, "UCAA-motif" RNA Aptamers.

Authors:  Angela S Whatley; Mark A Ditzler; Margaret J Lange; Elisa Biondi; Andrew W Sawyer; Jonathan L Chang; Joshua D Franken; Donald H Burke
Journal:  Mol Ther Nucleic Acids       Date:  2013-02-05       Impact factor: 10.183

7.  Aptamer-based therapeutics: new approaches to combat human viral diseases.

Authors:  Ka-To Shum; Jiehua Zhou; John J Rossi
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-25

8.  Efficient HIV-1 inhibition by a 16 nt-long RNA aptamer designed by combining in vitro selection and in silico optimisation strategies.

Authors:  Francisco J Sánchez-Luque; Michael Stich; Susanna Manrubia; Carlos Briones; Alfredo Berzal-Herranz
Journal:  Sci Rep       Date:  2014-09-01       Impact factor: 4.379

9.  High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication.

Authors:  Sonald Duclair; Archana Gautam; Andrew Ellington; Vinayaka R Prasad
Journal:  Mol Ther Nucleic Acids       Date:  2015-02-17       Impact factor: 10.183

10.  Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.

Authors:  Ka Ming Pang; Daniela Castanotto; Haitang Li; Lisa Scherer; John J Rossi
Journal:  Nucleic Acids Res       Date:  2018-01-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.